Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges

Apr 14, 2018Current clinical pharmacology

Using Tiny Medicine Particles to Treat Brain Tumors by Crossing the Blood-Brain Barrier

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

This review highlights advances in drug delivery methods to improve treatment for brain tumors.

Ongoing research shows that using nanomedicines can enhance the delivery of anticancer drugs across the blood-brain barrier (BBB) and blood-tumor barrier (BTB).
Innovative drug delivery agents, such as liposomes and polymeric nanoparticles, may improve the effectiveness of anticancer therapies targeting brain tumor cells.
Large conductance calcium-activated potassium channels and ATP-dependent potassium channels are identified as potential pathways for enhanced delivery of cancer treatments.
New pharmaceutical strategies are being developed to facilitate targeted delivery of drugs to brain tumors while avoiding drug resistance mechanisms.
Research suggests that combining BTB modulators with traditional anticancer drugs could lead to improved therapeutic outcomes.

AI simplified

BACKGROUND: This review elucidates ongoing research, which show improved delivery of anticancer drugs alone and/ or enclosed in carriers collectively called nanomedicines to cross the BBB/ BTB to kill tumor cells and impact patient survival. We highlighted various advances in understanding the mechanism of BTB function that has an impact on anticancer therapeutics delivery. We discussed latest breakthroughs in developing pharmaceutical strategies, including nanomedicines and delivering them across BTB for brain tumor management and treatment.

METHODS: We performed an extensive literature search and highlighted important studies on the regulation of BTB permeability with respect to nanotech-based nanomedicines for targeted treatment of brain tumors. We have reviewed research articles that describe the development of specialized molecules and nanospheres, which carry payload of anticancer agents to brain tumor cells across the BBB/ BTB and avoid drug efflux systems. We highlighted research on the identification and development of targeted anti-cancer drug delivery to brain tumors. In addition, we discussed multimeric molecular therapeutics and nanomedicines that were encapsulated in nanospheres for treatment and monitoring of brain tumors.

RESULTS: In this context, we quoted our research on large conductance calcium-activated potassium channels (BKCa) and ATP-dependent potassium channels (KATP) as portals of enhanced antineoplastic drugs delivery. We showed that several innovative drug delivery agents such as liposomes, polymeric nanoparticles, dendrimers and many such tools can be utilized to improve anticancer drugs and nanomedicines across the BTB to reach brain tumor cells.

CONCLUSION: This review might interest both academic and drug company scientists involved in drug delivery to brain tumors. We further seek to present evidence that BTB modulators can be clinically developed as combination drug or/ and as stand-alone anticancer drugs. Eventually, it is expected that unrelenting effort from the scientific community in developing novel drug delivery methods should increase the survival rate of brain tumor patients, which is dismally low presently.

Full Text

Full text is available at the source.

View full text ↗

Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief